Experimental injection targets tough blood cancers and anemia
NCT ID NCT07205315
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-stage study tests a new treatment called GT801 in 28 adults with certain blood cancers (like leukemia and lymphoma) or an autoimmune blood disorder (AIHA) that have not responded to standard therapies. The treatment uses specially modified cells to target a protein called CD19 on cancer and immune cells. The main goals are to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Zhengzhou Yihe Hospital
RECRUITINGZhengzhou, Henan, 450018, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.